Stock Events

Stock Events

Vera Therapeutics 

$40.23
48
+$2.13+5.59% Wednesday 07:00

Statistics

Day High
40.23
Day Low
38.07
52W High
-
52W Low
-
Volume
35
Avg. Volume
-
Mkt Cap
2.87B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2025
Q4 2025
Next
-1.39
-1.31
-1.24
-1.16
Expected EPS
-1.328378
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-599.23MNet Income

Analyst Ratings

$82.25Average Price Target
The highest estimate is 110.00.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy
88%
Hold
13%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VERA.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is a biopharmaceutical company that competes in the development of treatments for various diseases, including those in Vera Therapeutics' focus areas.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie operates in similar therapeutic areas as Vera Therapeutics, including immunology and chronic diseases, making it a direct competitor.
AMGEN
AMGN
Mkt Cap160.66B
Amgen focuses on human therapeutics, including treatments for serious illnesses, overlapping with Vera Therapeutics' research and development efforts.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb is involved in discovering, developing, and delivering innovative medicines that address serious diseases, competing with Vera Therapeutics.
Pfizer
PFE
Mkt Cap140.15B
Pfizer develops and produces medicines and vaccines for a wide range of medical disciplines, including areas where Vera Therapeutics is active.
Novartis
NVS
Mkt Cap237.61B
Novartis focuses on patented medicines, generics, and biosimilars, with a broad portfolio that competes with Vera Therapeutics' offerings.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical segment, competes across various therapeutic areas, including those targeted by Vera Therapeutics.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals specializes in the discovery, development, and commercialization of medicines for serious conditions, aligning as a competitor to Vera Therapeutics.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is known for creating transformative medicines for people with serious diseases, directly competing with Vera Therapeutics' mission.
Biogen
BIIB
Mkt Cap22.63B
Biogen focuses on developing therapies for neurological and neurodegenerative diseases, competing in the broader biopharmaceutical space with Vera Therapeutics.

About

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Show more...
CEO
ISIN
US92337R1014

Listings

BOATS
BOATS
VERA.BOATS
XNAS
US
VERA

0 Comments

Share your thoughts

FAQ

What is Vera Therapeutics stock price today?▼
The current price of VERA.BOATS is $40.23 USD — it has increased by +5.59% in the past 24 hours. Watch Vera Therapeutics stock price performance more closely on the chart.
What is Vera Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Vera Therapeutics stocks are traded under the ticker VERA.BOATS.
What is Vera Therapeutics market cap?▼
Today Vera Therapeutics has the market capitalization of 2.87B
When is the next Vera Therapeutics earnings date?▼
Vera Therapeutics is going to release the next earnings report on May 07, 2026.
What were Vera Therapeutics earnings last quarter?▼
VERA.BOATS earnings for the last quarter are -1.39 USD per share, whereas the estimation was -1.32 USD resulting in a -4.92% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Vera Therapeutics revenue for the last year?▼
Vera Therapeutics revenue for the last year amounts to 0 USD.
What is Vera Therapeutics net income for the last year?▼
VERA.BOATS net income for the last year is -599.23M USD.
When did Vera Therapeutics complete a stock split?▼
Vera Therapeutics has not had any recent stock splits.